Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Novan, Inc. (NASDAQ: NOVN).

Full DD Report for NOVN

You must become a subscriber to view this report.


Recent News from (NASDAQ: NOVN)

SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment
MORRISVILLE, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s onychomycosis development program with SB208 gel demonstrated an enhanced nail growth rate in adult females and will be presented May ...
Source: GlobeNewswire
Date: May, 17 2018 08:05
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program
SB414 – Nitric Oxide-Releasing Cream – Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting Key Inflammatory Cytokines IL-4 and IL-13 in Atopic Dermatitis to be presented at International Investigative Dermatology Meeting MORRIS...
Source: GlobeNewswire
Date: May, 15 2018 08:09
Editor's Notes: Flipping The Script On Alibaba During Earnings Season
We’re flush in earnings season and that tends to shake out some opportunities one way or another. The best investors can anticipate when an earnings move is going to happen, right? Or maybe they wait and then act when the facts are in. Or they pay attention to the long-term, slotting in...
Source: SeekingAlpha
Date: May, 04 2018 09:45
Novan Advances Organization and Strengthens Leadership Team
CEO Role No Longer “Interim” Clinical Operations Role Established Finance Team Positioned for the Future MORRISVILLE, N.C., April 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced a number of key leadership and tale...
Source: GlobeNewswire
Date: April, 12 2018 07:05
Zuckerberg On Safari To Washington
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Facebook (FB) founder Mark Zuckerberg treks to Capitol Hill next week for an appear...
Source: SeekingAlpha
Date: April, 07 2018 09:28
Dermira Tumbles On Phase 3 Data For Acne, But Hope Remains
On Monday, Dermira ( DERM ) announced that it had failed two phase 3 trials using its topical gel olumacostat glasaretil ((DRM01)). Both of these trials were treating patients with acne. It is really bad that the company did not succeed in either study, but that doesn't mean that it is the e...
Source: SeekingAlpha
Date: March, 06 2018 07:30
Dr. Eugene Sun Appointed to Novan Board of Directors
Complements existing Board expertise as 30-year clinician, drug developer and former biopharmaceutical CEO Will provide expert perspective on the clinical application of the underlying nitric oxide science Will chair newly formed Research and Development Committee   MORRISVIL...
Source: GlobeNewswire
Date: February, 21 2018 08:00
Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
MORRISVILLE, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s two Phase 3 clinical trials and long-term safety trial with SB204 for the treatment acne vulgaris will be presented during a Late-bre...
Source: GlobeNewswire
Date: February, 13 2018 08:05
Mid-stage study underway evaluating Novan's SB206 in contagious skin infection
The first patient has been dosed in a Phase 2 clinical trial assessing Novan's (NASDAQ: NOVN ) SB206 for the treatment of molluscum contagiosum (MC), a contagious skin infection caused by molluscipoxvirus . More news on: Novan, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: January, 25 2018 09:26
Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum con...
Source: GlobeNewswire
Date: January, 25 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-142.622.562.642.5535,624
2018-08-132.572.5652.632.5617,778
2018-08-102.76722.5852.76722.58535,439
2018-08-092.662.6752.79022.6517,068
2018-08-082.892.762.892.7116,491

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1422515,0991.4902Cover
2018-08-131,2561,46585.7338Short
2018-08-102,5595,15449.6508Short
2018-08-091,5604,47734.8448Cover
2018-08-083,7726,52557.8084Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NOVN.


About Novan, Inc. (NASDAQ: NOVN)

Logo for Novan, Inc. (NASDAQ: NOVN)

Not available

 

Contact Information

 

 

Current Management

  • Jeff N Hunter / EVP, CBO
  • Andrew J. Novak / Vice President, Chief Accounting Officer, Principal Acct. Officer
    • Mr. Novak, age , has served as the Company s Director of Financial Reporting and Analysis since June and Senior Director of Financial Reporting and Analysis since March . From June until March , Mr. Novak served as Director of Financial and SEC Reporting for Scynexis, Inc., a biotechnology company. Prior to joining Scynexis, Inc., Mr. Novak served as an Audit Manager at Deloitte amp Touche from September to October and as a Technical Manager, Accounting amp Audit Publications for the American Institute of Certified Public Accountants from October to June . Mr. Novak is a certified public accountant and holds both a Bachelor of Science in Business Administration, Finance and a Master of Science in Accountancy from the University of North Carolina at Wilmington.

Current Share Structure

  • Market Cap: $81,761,650 - 05/11/2018
  • Issue and Outstanding: 26,038,742 - 03/23/2018

 


Recent Filings from (NASDAQ: NOVN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: NOVN)

Daily Technical Chart for (NASDAQ: NOVN)


Stay tuned for daily updates and more on (NASDAQ: NOVN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NOVN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NOVN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of NOVN and does not buy, sell, or trade any shares of NOVN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/